Mounjaro vs Zepbound: One Tirzepatide, Two Names

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

A PlexusDx Education Hub explainer for anyone puzzled that one tirzepatide molecule carries two market identities. Browse the Peptides & GLP-1 Education Hub

This is an independent editorial comparison; PlexusDx has no commercial relationship with the manufacturers of the products discussed.

Mounjaro and Zepbound are the same tirzepatide molecule sold under two Eli Lilly names, yet they show up as if they were competitors. As of April 2026, this explainer clarifies how one molecule earns two labels, situates it within the broader incretin class, and points to the pathway biology no brand name changes.

One tirzepatide molecule, two market identities

Mounjaro (tirzepatide, Eli Lilly) and Zepbound (tirzepatide, Eli Lilly) are the same GLP-1 pathway compound. Tirzepatide is a GIP/GLP-1 dual agonist; semaglutide, liraglutide, and dulaglutide are GLP-1-selective; retatrutide is an investigational GLP-1/GIP/glucagon triple agonist not FDA-approved as of April 2026. Both labels act on the GLP-1 receptor to influence gastric emptying, glucose excursions, and satiety in exactly the same way.

How the class earned its FDA approvals

Across the incretin field, approvals are indication-specific: Ozempic (semaglutide) for type 2 diabetes in 2017; Wegovy (semaglutide 2.4 mg) for chronic weight management in 2021; Rybelsus (oral semaglutide) for diabetes in 2019; Mounjaro (tirzepatide) for diabetes in 2022; Zepbound (tirzepatide) for weight management in 2023 and obstructive sleep apnea in 2024 (SURMOUNT-OSA); Trulicity (dulaglutide) in 2014; Victoza (liraglutide) in 2010. Retatrutide remains investigational.

Trials that built the evidence base

Each program answered a different question. STEP covered semaglutide for weight management; SUSTAIN and SELECT covered semaglutide for diabetes and cardiovascular outcomes; SURMOUNT and SURPASS covered tirzepatide for weight and diabetes; SURMOUNT-OSA addressed sleep apnea; LEAD and LEADER covered liraglutide; AWARD covered dulaglutide. Because head-to-head data is limited — SUSTAIN 7 and SURPASS-2 aside — results are most accurately read one trial at a time.

The warning label every incretin drug carries

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk seen in rodent studies, and all are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects are most common; rare serious events include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

Where list prices land across the field

As of April 2026, list prices for the FDA-approved brands range roughly $815 to $1,620 per month at U.S. list (manufacturer published pricing). Because Mounjaro and Zepbound share a molecule, the more relevant driver of cost is not the compound but the label's indication and coverage. Actual out-of-pocket spend depends on insurance, savings card eligibility, the prescribed indication, and compounded-alternative availability through a licensed pathway.

The pathway biology no brand name changes

Since Mounjaro and Zepbound deliver identical tirzepatide, the genetic terrain is the same for both. Variants in FTO (appetite and adiposity set-point), GLP1R (the GLP-1 receptor), MC4R (energy balance), and TCF7L2 (glucose homeostasis and GLP-1 secretion) map the baseline biology tirzepatide works across. They are pathway-level and do not predict response. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — and the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R, and TCF7L2.

More from the Hub: Mounjaro cost comparison, Mounjaro savings options, how to obtain Mounjaro, and the Mounjaro injection format.

For the record, this content is educational only. Across the GLP-1 category PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and does not sell, prescribe, or recommend any other therapeutic peptide, including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds. The Precision Peptide Genetic Test describes how genes influence peptide-related pathways; it does not predict your response to any specific medication. Please consult a qualified healthcare provider before starting any peptide protocol.

Begin upstream: take the Precision Peptide Genetic Test, or browse the Weight Management Protocols to compare formats. Browse the Peptides & GLP-1 Education Hub

Frequently Asked Questions

Why does Lilly market the same molecule under two names?

Separate brand names let one tirzepatide molecule carry distinct FDA indications: Mounjaro is the diabetes-labeled presentation and Zepbound the weight-management-labeled one. This is common in the category and shapes prescribing and insurance coverage, since payers evaluate claims against the indication attached to each label.

Does a shared molecule mean identical results?

The pharmacology is identical because the active ingredient is the same, but outcomes still vary with indication, dose, and individual biology. Trials for each label targeted different populations and endpoints, so results are read per-trial. Discuss what any comparison means for you with a healthcare provider.

Does the genetic test read differently for each brand?

No. Because Mounjaro and Zepbound are the same molecule, no test could distinguish them by response, and this one does not predict response to any medication. It reads pathway-level variants — FTO, MC4R, and TCF7L2 — describing your baseline tirzepatide-relevant biology.

What explains the price gap between the two labels?

Eli Lilly prices the labels independently, so their figures within the roughly $815 to $1,620 April 2026 band differ despite the shared molecule. List price is not out-of-pocket cost, which depends on coverage, savings programs, the prescribed indication, and compounded-alternative availability.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.